Hyperlipidemia Flashcards

1
Q

Leading cause of death in US

A

CVD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How adherent to statins must you be before you get benefits?

A

80%

6 months after initiation of statin therapy, adherence rates are 40-65%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What’s the history of statin trials?

A

Two types of trials:
primary prevention – patients without evidence of CVD
secondary prevention – patients with CVD
Both types demonstrate reductions in mortality and number of cardiovascular events

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How do you establish very high risk according to ATPIII guidelines?

A
Very high risk= established CVD + 
Major risk factors (especially DM)
Severe and poorly controlled risk factors (especially continued smoking)
Multiple RFs of the metabolic syndrome 
Acute coronary syndromes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Definition and Goal/initiation LDL level for high risk

A

CHD or CHD risk equivalent
LDL goal is 100 (or 70 for very high risk)
If LDL ≥ 100: Initiate TLC and pharmaceutical treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Definition and initiation LDL level for moderately high risk

A

2+ risk factors (10 year risk 10-20%)
130 - lifestyle interventions
If LDL ≥ 160: Initiate pharmaceutical treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Definition and initiation LDL level for moderate risk

A

2+ risk factors (<10% 10 year risk)

130

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Definitions and Goal/initiation LDL level for lower risk

A

0-1 risk factors
If LDL ≥ 160: Initiate TLC (therapeutic lifestyle changes)
If LDL ≥ 190: Initiate pharmaceutical treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are lipids? (differentiate between kinds)

A

Chylomicrons transport fats from intestinal mucosa to liver
In the liver, the chylomicrons release triglycerides and some cholesterol and become low-density lipoproteins (LDL)
LDL then carries fat and cholesterol to the body’s cells
High density lipoproteins (HDL) carry fat and cholesterol back to the liver for excretion
When oxidized LDL cholesterol gets high, atheroma formation in the walls of arteries occurs, which causes atherosclerosis
HDL cholesterol is able to go and remove cholesterol from the atheroma
Atherogenic cholesterol = LDL, VLDL, IDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Causes of HLD

A
Diet
Hypothyroidism
Nephrotic syndrome
Anorexia nervosa
Obstructive liver disease
Obesity
Diabetes mellitus
Pregnancy
Acute hepatitis
Systemic lupus erythematousus
AIDS (protease inhibitors)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Dietary sources of cholesterol (differentiate between what kinds of fat, sources, and what kind of cholesterol levels they raise)

A

monosatured

  • olives, olive oil, canola, peanut, cashews, almonds, most nuts; avocados
  • lowers LDL, raises HDL

polyunsaturated

  • corn, soybean, safflower and cottonseed oil, fish
  • lowers LDL, raises HDL

saturated

  • whole milk, butter, cheese, and ice cream; red meat; chocolate; coconuts, coconut milk, coconut oil, egg yolks, chicken skin
  • raises both LDL and HDL

transfats

  • margarines; vegetable shortening; partially hydrogenated vegetable oil; deep-fried chips; many fast foods; most commercial baked goods
  • raises LDL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Types of hereditary HLD

A

Familial Hypercholesterolemia (most common)
Codominant genetic disorder, occurs in heterozygous form
Occurs in 1 in 500 individuals
Mutation in LDL receptor, resulting in elevated levels of LDL at birth and throughout life
High risk for atherosclerosis, tendon xanthomas (75% of patients), tuberous xanthomas and xanthelasmas of eyes.
Familial Combined Hyperlipidemia (increased chol/trigs)
Autosomal dominant
Increased secretions of VLDLs
Dysbetalipoproteinemia
Affects 1 in 10,000
Results in apo E2, a binding-defective form of apoE (which usually plays important role in catabolism of chylomicron and VLDL)
Increased risk for atherosclerosis, peripheral vascular disease
Tuberous xanthomas, striae palmaris

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

types of tests for lipid levels

A

Nonfasting lipid panel
measures HDL and total cholesterol
Fasting lipid panel
Measures HDL, total cholesterol and triglycerides
LDL cholesterol is calculated:
LDL cholesterol = total cholesterol – (HDL + triglycerides/5)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

ATPIII guidelines of when to check lipids

A

Beginning at age 20: obtain a fasting (9 to 12 hour) serum lipid profile consisting of total cholesterol, LDL, HDL and triglycerides
Repeat testing every 5 years for acceptable values

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

USPSTF guidelines for checking lipids

A

Women aged 45 years and older, and men ages 35 years and older undergo screening with a total and HDL cholesterol every 5 years.
If total cholesterol > 200 or HDL <40, then a fasting panel should be obtained
Cholesterol screening should begin at 20 years in patients with a history of multiple cardiovascular risk factors, diabetes, or family history of either elevated cholester0l levels or premature cardiovascular disease.
Direct evidence regarding benefits and harms of dyslipidemia screening or treatment in younger adults remains unavailable (2016)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

ATPIII goals for lipid levels

A
LDL
< 100 →Optimal
100-129 → Near optimal
130-159 → Borderline
160-189→ High
≥ 190 → Very High
Total Cholesterol
< 200 → Desirable
200-239 → Borderline 
≥240 → High	
HDL
< 40 → Low
≥ 60 → High
Serum Triglycerides
< 150 → normal
150-199 → Borderline
200-499 → High
≥ 500 → Very High
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

8 JNC risk factors for determining LDL goals

A

Cigarette smoking
Hypertension (BP ≥140/90 or on anti-hypertensives)
Low HDL cholesterol (< 40 mg/dL)
Family History of premature coronary heart disease (CHD) (CHD in first-degree male relative <55 or CHD in first-degree female relative < 65)
Age (men ≥ 45, women ≥ 55)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

High risk/CHD/CHD Risk Equivalent

A
CHD and CHD Risk Equivalents:
Peripheral Vascular/Arterial Disease
Cerebral Vascular Accident
Diabetes Mellitus
MI
Stroke
Imaging evidence of atherosclerosis
AAA
Symptomatic CAD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Framingham Heart Study

A

General Cardiovascular Risk Profile for Use in Primary CareFramingham risk score effective, but only predicts CHD risk (not stroke etc.)
CV diseases share common risk factors
Set out to develop a way to predict risk for all CVD events It builds on prior models by:
Adding HDL
Being based on study with more events
Estimating absolute CV risk

Allows prediction of all CV events
Stroke, CAD, PVD, CHF

20
Q

who should you do a Framingham Risk Assessment on?

A
For patients with multiple (2+) risk factors
Perform 10-year risk assessment
For patients with 0–1 risk factor
10 year risk assessment not required
Most patients have 10-year risk <10%
21
Q

Should you use statin in pts recovering from stroke?

A

In patients with recent stroke or TIA, treatment with 80 mg atorvastatin significantly reduced recurrent strokes and CV events when compared with placebo
There was a small increase in the incidence of hemorrhagic strokeHigh dose statins (started within 1-6 months) are proven effective
Starting statins in first 12 hours may be effective too—studies ongoing
Avoid stopping statins in pts with acute stroke
Benefit seen for all levels of cholesterol (elevated or not elevated)

22
Q

How are the new guidelines different from ATPIII?

A

No longer have therapeutic targets
New risk calculator
Use medications proven to reduce risk, i.e. STATINS
Avoid medications or supplements that may lower cholesterol number, but have no data to decrease CV risk
Focuses on treatment to reduce ASCVD events
Not a comprehensive approach to lipid management

23
Q

How do new guidelines define ASCVD?

A

CHD, stroke, PAD

24
Q

What is the goal of new guidelines?

A

identify those most likely to benefit from cholesterol-lowering statin therapy

25
Q

What does “healthy lifestyle” include?

A

Healthy diet
Regular exercise
No tobacco
Maintain “healthy” weight

26
Q

Healthy lifestyle recommendations based on ACC/AHA?

A

Dietary pattern rich in fruit, vegetables, whole grains, fish, low-fat dairy, lean poultry, nuts, legumes, and non-tropical oils consistent with DASH or Mediterranean diet
Restrict: saturated fats, trans fats, sweets, sugars, sugar-sweetened beverages, and sodium
Exercise: aerobic 40 minutes, 3X/week

27
Q

What are the 4 defined groups that could benefit from a statin under the new guidelines?

A
  1. Patients with clinical ASCVD
  2. LDL greater than 190 mg/dl
  3. Patients with DM, ages 40-75
  4. Age 40-75 years that do not meet above criteria, but have a 10 year risk > 7.5%
28
Q

Who is included in category “Patients with clinical ASCVD” under new guidelines?

A
CAD or PAD
Acute coronary syndromes
Coronary of other arterial revascularization
Stroke or TIA
PVD presumed to be atherosclerotic
29
Q

What are ways to identify clients with ASCVD?

A
Heart catheterization
Q waves on ECG
TEE
Coronary CTA
Non-invasive: Carotid duplex, UE/LE arterial duplex
Peripheral angiography
30
Q

Who is included under category “LDL greater than 190 mg/dl” in the new guidelines?

A

One of the few times level of cholesterol mentioned in guideline
For patients with familial hyperlipidemia
They deserve special consideration
Often may start with untreated LDL of 325-400 mg/dl

31
Q

Who is included in category “Patients with DM, ages 40-75” under the new guidelines?

A

All have indication for statin

Level of intensity of statin depends on 10 year risk

32
Q

Who is included in category “4. Age 40-75 years that do not meet above criteria, but have a 10 year risk > 7.5%” in the new guidelines?

A

10 year and lifetime risk as determined by CV Risk Calculator
Specifically designed for this trial
Downloadable on AHA or ACC site
Not without controversy, as the calculator has never been published or validated
Risk factors used: Sex, age, race, total cholesterol, HDL, Systolic BP, treated for HBP, DM, smoker
http://www.cvriskcalculator.com

33
Q

What is the new risk calculator for new guidelines?

A

Pooled cohort risk assessment

34
Q

What does the Pooled cohort risk assessment equation include?

A
"Gender"
Age
Race
Total cholesterol
HDL
Systolic BP
"receiving treatment for HTN?"
DM
Smoker
35
Q

When should you consider non-statin therapies?

A

only if: Less than anticipated response to statin, inability to tolerate a less than recommended intensity of statin, or complete statin intolerance
Adherence to lifestyle and statin therapy should be emphasized before addition of non-statin drug

36
Q

Other factors to consider when deciding how to manage HLD

A

Family history of premature CAD
LDL > 160 mg/dl
Increased CRP greater than 2.0 (high sensitivity)
Coronary calcium greater than 300 (correlates to atherosclerotic plaques)
ABI < 0.9

37
Q

What should you do about statin intolerance?

What is statin intolerance?

A

Readdress lifestyle issues
Decrease dose of statin
Try another statin
Check Vitamin D levels and replace
Evaluate for other conditions causing muscle weakness

38
Q

What is a high intensity statin?

A

High: defined as > 50% reduction of LDL with daily statin
All patients with CAD, regardless of age, should receive high intensity statin therapy if tolerated
High dose atorvastatin

39
Q

What is a moderate intensity statin?

A

Moderate: 30-50% reduction

simvastatin

40
Q

How do you treat a person with LDL > 190?

A

These patients get high intensity statin treatment
If they cannot tolerate high intensity statin therapy, use Zetia or other agent to achieve >50% reduction of baseline LDL.
Patients with FH are frequently unable to achieve previous goals even with multiple cholesterol lowering agents
In this special case, the authors felt that data has shown significant reductions of ASCVD by decreasing LDL > 50%
Can include statin plus another agent

41
Q

How do you treat a person with DM age 40-75?

A

Diabetics with > 7.5% 10 year risk get high intensity statin therapy
Diabetics with < 7.5% 10 year risk of CAD get moderate intensity statin therapy
Statin indicated in all patients with diabetes

42
Q

How do you treat a person with Non-diabetic with known CAD >7.5% 10 year risk?

A

Statin indicated in these patients

Moderate to high intensity statin therapy recommended

43
Q

In what higher risk conditions are there no new guidelines?

A
No indication for starting or discontinuing statins in the following:
NYHA class 2-4
Or those on dialysis
HIV patients
Solid organ transplant patients
Older adults >79 years
44
Q

What are some statin safety recommendations?

A

Select the appropriate dose
Keep potential side effects and drug-drug interaction in mind (Grade A)
If high or moderate intensity statin not tolerated, use the maximum tolerated dose instead
Check baseline ALT prior initiating the statin (Grade B)
Check LFTs if patient develops symptoms of hepatic dysfunction (Grade E)
If 2 consecutive LDL <40, consider decreasing the statin dose (Grade C, weak recommendation)
It may be harmful to initiate simvastatin 80mg, or increase the dose of simvastatin to 80mg (Grade B)

45
Q

What are injectable statins?

A

Repatha and Praluent every other week injections
Approved for patients with heterozygous familial hypercholesterolemia and rarer homozygous form of disease OR patients with CV disease who require additional cholesterol lowering
$$$$$: $14,560/year
More potent than Lipitor
Not known if use will translate into reduced number of heart attacks